eGFR Decline in Patients with IgAN Treated with Nefecon or Placebo: Results from the 2-year NEFIGARD Phase 3 Trial

Methods

- 18 years
- Primary IgAN
- eGFR 30-90 ml/min/1.73m²
- UPCR ≥0.8 g/g or PrU ≥ 1 g/24h w/RAASi

Endpoints: Time to reach ↓30 % in eGFR or kidney failure

Intervention

Screening
Optimized RAASi

Treatment double-blinded
Nefecon 16 mg/day
Placebo
9 months

Follow-up double-blinded
15 months of observation off the drug

Results

	Change in eGFR 9 months	Change in eGFR 24 months
Nefecon	+1.2%	-11%
Placebo	+8.2%	-21.5%

Outcomes

Risk of ↓ **30% in eGFR** ≈ irrespective of UPCR category (< or > 1.5 g/g)

Time to ↓ 30% in eGFR **slower** in Nefecon group HR 0.45; *p*=0.0014

↓ 41% in time-averaged **UPCR** in Nefecon group *p*<0.0001

Tx effect ≈ despite rescue medication.

AEs



Conclusion: These results strongly indicate that Nefecon preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.

Lafayette R, *et al*

VA by @GabyNeph

WCN'24